In The News

News article on the appointment of Adam George as Beckley Psytech’s new Independent Director, bringing nearly two decades of experience in the pharmaceuticals industry to the Board.

In The News

Beckley Psytech’s CEO Cosmo Feilding Mellen comments on 5-MeO-DMT’s potential to rival psilocybin as a cost-effective psychedelic treatment for depression and addiction.  

In The News

Exclusive news article on the Beckley Psytech’s partnership with Fluence to develop a psychedelic-assisted psychotherapy training programme for 5-MeO-DMT, featuring quotes from CEO Cosmo Feilding Mellen and Chief Medical Advisor Dr Fiona Dunbar.

In The News

Article on the life-changing effects of the rare headache condition SUNHA, featuring a quote from Beckley Psytech’s Chief Medical Advisor Dr Fiona Dunbar, on our upcoming clinical trial exploring psilocybin as a treatment.

In The News

Article featuring Beckley Psytech among the European companies set to dominate the psychedelic medicine market, with comments from CEO Cosmo Feilding-Mellen.

In The News

Article presenting the life-changing impact of the rare and debilitating headache condition SUNHA, mentioning Beckley Psytech’s upcoming clinical trial exploring the effects of psilocybin as a treatment.

In The News

News article on the £14m funding round to finance a drug development pipeline for 5-MeO-DMT, featuring quotes from CEO Cosmo Feilding-Mellen and investor James Bailey from Bail Capital. 

In The News

News article on the appointment of Andy Page as Beckley Psytech’s new Chief Operating Officer.

In The News

Article on the prospects for the psychedelic drugs market with comments from Beckley Psytech CEO Cosmo Feilding-Mellen following the news of the company’s latest £14m funding round.

In The News

Exclusive news article on the $18.6m funding round, featuring Beckley Psytech’s pitch deck and comments from CEO Cosmo Feilding-Mellen.